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Background: Axonal transport is vital for neurons and deﬁcits in this process have been previously reported in a
fewmousemodels of Alzheimer's disease prior to the appearance of plaques and tangles. However, it remains to
be determined whether axonal transport is defective prior to the onset of neurodegeneration. The rTg4510
mouse, a fronto-temporal dementia and parkinsonism-17 (FTDP-17) tauopathy model, over-express tau-
P301L mutation found in familial forms of FTDP-17, in the forebrain driven by the calcium–calmodulin kinase
II promoter. Thismousemodel exhibits tau pathology, neurodegeneration in the forebrain, and associated behav-
ioral deﬁcits beginning at 4–5 months of age.
Animal model: rTg4510 transgenicmice were used in these studies. Mice were given 2 μL of MnCl2 in each nostril
1 h prior to Magnetic Resonance Imaging (MRI). Following MnCl2 nasal lavage, mice were imaged using Manga-
nese enhanced Magnetic Resonance Imaging (MEMRI) Protocol with TE= 8.5 ms, TR= 504 ms, FOV= 3.0 cm,
matrix size = 128 × 128 × 128, number of cycles = 15 with each cycle taking approximately 2 min, 9 s, and
24 ms using Paravision software (BrukerBioSpin, Billerica, MA). During imaging, body temperature was main-
tained at 37.0 °C using an animal heating system (SA Instruments, Stony Brook, NY).
Data analysis: Resulting images were analyzed using Paravision software. Regions of interest (ROI) within the ol-
factoryneuronal layer (ONL) and thewater phantomconsisting of onepixel (ONL) and9 pixels (water)were select-
ed and copied across each of the 15 cycles. Signal intensities (SI) of ONL andwater phantomROIsweremeasured. SI
values obtained for ONL were then normalized the water phantom SI values. The correlation between normalized
signal intensity in the ONL and time were assessed using Prism (GraphPad Software, San Diego, CA).
Results:Using theMEMRI technique on 1.5, 3, 5, and 10-month old rTg4510mice and littermate controls, we found
signiﬁcant axonal transport deﬁcits present in the rTg4510mice beginning at 3 months of age in an age-dependent
manner. Using linear regression analysis, wemeasured rates of axonal transport at 1.5, 3, 5, and 10 months of age in
rTg4510 andWTmice. Axonal transport rates were observed in rTg4510mice at 48% ofWT levels at 3 months, 40%
of WT levels at 5 months, and 30% of WT levels at 10 months of age. In order to determine the point at which tau
appears in the cortex, we probed for phosphorylated tau levels, and found that pSer262 is present at 3 months of
age, not earlier at 1.5 months of age, but observed no pathological tau species until 6 months of age, months after
the onset of the transport deﬁcits. In addition, we saw localization of tau in the ONL at 6 months of age.
Discussion: In our study,we identiﬁed thepresence of age-dependent axonal transport deﬁcits beginning at 3 months
of age in rTg4510 mice. We correlated these deﬁcits at 3 months to the presence of hyperphosphorylated tau in
the brain and the presence within the olfactory epithelium. We observed tau pathology not only in the soma of
these neurons but also within the axons and processes of these neurons. Our characterization of axonal transport
in this tauopathy model provides a functional time point that can be used for future therapeutic interventions.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ouston, TX 77030, USA.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fronto-temporal dementia (FTD) is a neurodegenerative disorder
that accounts for approximately 20% of all pre-senile dementia cases
(Wszolek et al., 2006). It is characterized by changes in reasoning,
movement, speech, and language and primarily affects the frontal and
anterior temporal lobes in the brain (Ingram and Spillantini, 2002). Di-
agnosis of FTD is difﬁcult due to the fact that patients can display a wide
variation in the severity of symptoms. Over the past quarter century, a
proportion of FTD cases have been discovered to have a strong familial
component. One of these includes FTD with parkinsonism (FTDP-17)
(Wszolek et al., 2006). This form of FTD is associatedwith tau tangle pa-
thology due to mutations in the microtubule associated protein tau
(MAPT) gene on chromosome 17 (Wszolek et al., 2006). Current thera-
pies have focused on delaying disease progression, but have been limit-
ed in their success. Part of the challenge in this area is identifying an
optimal time point for intervention.
Autopsies from FTDP-17 patients have revealed neuroﬁbrillary tau
tangle pathology in the frontal and temporal lobes of the brain
(Wszolek et al., 2006); (Snowden et al., 2002); (Goedert et al., 2012).
The tau mutations in FTDP-17 have been linked to two major patholog-
ical outcomes (Combs and Gamblin, 2012). The ﬁrst of these is disrup-
tion in alternative splicing that leads to a higher ratio of 4R tau rather
than 3R tau. The second being the disruption of tau binding to microtu-
bules in neurons, causing the accelerated accumulation of aggregate
forms of tau as well as an increase in the formation of tau ﬁlaments
(Wszolek et al., 2006). One of the more predominant mutations in the
tau gene that is associated with FTDP-17 is the P301L mutation (Bird
et al., 1999). This mutation results in a phenotype where the average
age of onset is between 41 and 50 years, and is more associated with a
personality change rather than with parkinsonism (Wszolek et al.,
2006). However, most familial mutations causing FTDP-17 have been
linked to tau's role inmicrotubule stabilization and assembly in neurons
due to their presence in the coding regions of the tau gene. Finally, in
FTDP-17 autopsy samples, tau oligomers have been identiﬁed and also
have been demonstrated to propagate endogenous tau pathology in
the brain (Lasagna-Reeves et al., 2012); (Goedert and Spillantini,
2011); (Karch et al., 2012).
The protein-coding region of tau encodes genes involved in axonal
transport, or the transport of organelles and vesicles from the soma to
the synapse of neurons. Organelles such asmitochondria and lysosomes
are transported via both anterograde and retrograde axonal transport
(Chevalier-Larsen and Holzbaur, 2006; Seamster et al., 2012). In addi-
tion, the role of axonal transport has been studied inmodels of neurode-
generative diseases such as ALS and Alzheimer's disease (Bearer, 2012);
(Seamster et al., 2012; Smith et al., 2007; Zhang et al., 2004). For exam-
ple, several studies in patient cell lines (Schulz et al., 2012; Trimmer and
Borland, 2005) as well as in vivomodels of neurodegenerative diseases
have demonstrated deﬁcits in this process prior to the onset of overt pa-
thology (Kim et al., 2011); (Chevalier-Larsen andHolzbaur, 2006; Smith
et al., 2010; Trimmer and Borland, 2005). Measuring axonal transport
in vivo is very challenging. Manganese-enhanced MRI (MEMRI) is one
of the few unique methods for axonal transport assessments in a non-
invasive manner (Massaad et al., 2010; Smith et al., 2010); (Silva
et al., 2004). MEMRI utilizes the presence of Ca2+ channels in neurons
in order to enter cells and be transported down their axons (Inoue
et al., 2011). MEMRI has many applications and has been used to mea-
sure rates of transport in models of both hyperglycemia as well as
Alzheimer's disease (Kim et al., 2009) (Fu-Hua Wang, 2012). MEMRI
can also be used to measure synaptic strength in vivo (Serrano et al.,
2008). For example, in the amyloid overproducing Tg2576 mouse
model, axonal transport deﬁcits were detected using MEMRI prior to
the onset of amyloid plaque deposits in the brains of thesemice, indicat-
ing that the method reliably and sensitively can detect such deﬁcits
in vivo and such deﬁcits more importantly precede disease pathology
(Smith et al., 2007); (Massaad et al., 2010). In addition, a studydemonstrated that WT human tau in a model lacking APP was enough
to signiﬁcantly worsen in vivo axonal transport deﬁcits (Smith et al.,
2010). Other studies have also demonstrated that axonal transport
rates are unaffected by tau deletion or over-expression (Perez et al.,
2013; Yuan et al., 2008). Furthermore, other studies using mouse
models of tauopathy have implicated ex vivo deﬁcits in axonal transport
at late stages in disease progression post tau pathology (Zhang et al.,
2004); (Zhang et al., 2010).
In this study, we characterized axonal transport deﬁcits in the
rTg4510 transgenic line, amousemodel of FTDP-17. Thiswell character-
ized model carry the human P301L mutation found in several FTDP-17
cases (Combs and Gamblin, 2012). The expression of P301L tau in the
forebrain is driven by the calmodulin kinase II (CaMKII) promoter. It
has also been demonstrated that the CaMKII promoter has been
shown to drive expression in the olfactory bulb (Liu, 2000). The pheno-
type of this mouse has also been used to test biomarker serum levels for
tau spinal ﬂuid levels, as well as several potential antioxidant bio-
markers (Kopeikina et al., 2011); (Berger et al., 2007). Additionally, sev-
eral learning and memory assays have been used to characterize the
model, and these indicate a progressive, age-related decline in both
short and long term memory beginning at 4 months of age (Yue et al.,
2011); (Ludvigson et al., 2011). Anatomical MRI studies have also
been conducted in thismousemodel at critical points in the disease pro-
cess, demonstrating that neurodegeneration is isolated to the forebrain
(Kopeikina et al., 2011). A recent study using the MEMRI technique has
indicated a correlation between neuronal transport and tangle patholo-
gy in an alternatemodel (JNPL3) of tauopathy (Bertrand et al., 2013). In
this study, the authors longitudinally characterized JNPL3 mice for their
pathology and correlated peak values of transport rates. However, to
date, a characterization of axonal transport with extensive tau isoform
characterizations at each age point has not been conducted in a well-
characterized FTDP-17 model such as the rTg4510 mouse model of
tauopathy.
Here, we characterized axonal transport rates in the rTg4510mouse
model of tauopathy and correlated these rates to the onset of tau tangle
pathology in the mouse. Our data show that axonal transport deﬁcits
precede the deposition of tau aggregates and the formation of tau ﬁbril-
lary tangles that are typically associated with cognitive deﬁcits.
2. Materials and methods
2.1. Mice and genotyping
For this study, we used mice that over-express the P301L mutation
in 4R0N human tau associated with FTDP-17. The generation of rTg
(tauP301L) 4510mice (abbreviated as rTg4510mice) has been described
previously (Berger et al., 2007; Ludvigson et al., 2011). These transgenic
micewere generated by F1 crossing of responder mice carrying tauP301L
cDNA with an upstream tetracycline-operon responsive element (ab-
breviated as P301L) and activator mice containing a trans-activator
gene consisting of the tetracycline-off open reading frame placed down-
stream of the CaMKII promoter (abbreviated as tTA). Both transgenic
lines were gifts from Michael Hutton (Mayo Foundation) and Karen
Ashe (University of Minnesota Medical School). Littermates lacking
both the responder transgenes (P301L) and activator (tTA) were used
as wild-type controls (NTg). For all groups, both male and female mice
were used, and pilot studies were conducted prior to data collection to
conﬁrm that there were no sex differences in these measurements.
Mouse genotypes were determined from tail biopsies using real-
time qPCRwith speciﬁc probes designed for each gene by a commercial
service (Transnetyx, Cordova, TN, USA). For accurate genotyping, tail
tissues from mice were digested overnight in extraction buffer
(50 mM KCl; 10 mM Tris–HCl (pH 9.0); 0.1% Triton X-100; 0.4 mg/mL
Proteinase K) at 55 °C to extract genomic DNA. Human tau and
CAMKII transgene were detected using the following primers: CamKII
tTa forward (5′-CGC TGT GGG GCA TTT TAC TTT-3′); CamKII tTa reverse
713T. Majid et al. / NeuroImage: Clinical 4 (2014) 711–717(5′-CAT GTC CAG ATC GAA ATGGTC-3′), human tau-exon1 forward (5′-
TGAACCAGGATGGCTGAGC-3′); andhuman tau-exon5 reverse (5′-TTGT
CATCGCTTCCAGTCC-3′). PCR cycling conditionswere: 94 °C (5 min), 94
°C (30 s)+ 60 °C (30 s)+ 72 °C (45 s) for 30 cycles, and 72 °C (10min)
using Econo Taq Plus GreenMasterMix (Lucigen Corp., Middleton,WI).
Animal housing and usewere in compliancewith theNIHGuidelines for
the Care and Use of Laboratory Animals and were approved by the insti-
tutional animal care committee at Baylor College ofMedicine. The num-
bers of mice used per ﬁgure are described in Supplementary Table 1.
2.2. Manganese administration
Mice were anesthetized with 5% isoﬂuorane in 100% O2 for 2 min
in order to administer a nasal lavage of 4 μL of 0.75 g/mL MnCl2 dis-
solved in nanopure water. Once this was administered, the animals
were placed back into their cage and allowed to recover. One hour
after lavage administration, the mice were exposed to 5% isoﬂurane
and then carefully exposed to 2% isoﬂurane in 100% O2 for imaging.
Mice were then placed in a head holder while respiratory rate was
monitored and temperature was maintained at 37 °C. This was
done using an air heating systemwith theModel 1025 Small Animal
Monitoring and Gating System Software (SA Instruments, Inc.).
2.3. MRI
All images in this study were acquired with a 9.4T, Bruker Avance
Biospec Spectrometer, 21 cmbore horizontal scannerwith a 35mmvol-
ume resonator (Bruker Biospin, Billerica, MA). Imaging parameters of
the olfactory MEMRI scans were: TE = 8.536 ms, TR = 504 ms, FOV =
30 mm2, slice thickness = 1 mm, matrix = 128 × 128, NEX = 2, and
number of cycles = 15 (each cycle taking about 2 min) to acquire
using Paravision software (Bruker Biospin, Billerica, MA). The scan
was a RARE sequence scan that was modiﬁed to have 6 slices per
cycle. The ﬁrst slice was consistently aligned at the most posterior
point of the olfactory bulb to ensure slice reproducibility from mouse
to mouse for the MEMRI scans.
2.4. MRI data analysis
All scans were analyzed using Paravision software (Bruker Biospin,
Billerica, MA). The length of the olfactory bulb was measured and a
line was placed on the image. From the midpoint of this line, a 90-
degree angle was drawn, extending outward towards the ONL, where
the region of interest (ROI)was selected. Signal intensitywasmeasured
in a ROI of one pixel in the olfactory neuronal layer (ONL) on the right
side of the olfactory bulb, due to a chemical shift artifact present on
the left side of the bulb (Sbarbati et al., 2002); (Smith et al., 2007).
One pixel was selected due to the pixel representing one fascicle of
axons that project into the olfactory neuronal layer. Single glomeruli
are the target of these fascicles and one pixel minimizes outside varia-
tion from other fascicles within the olfactory epithelium (Akins and
Greer, 2006). Another ROI of nine pixels was used to measure signal in-
tensity in the water phantom. All ONL ROIs were normalized to water
phantom ROIs for 15measurements, which correspond to the 15 cycles
in the scan in order to account for any differences in the shimming from
mouse to mouse. This normalized signal intensity was used to plot 15
measurements per mouse. The slope of this line was then established
as the axonal transport rate for each mouse. For statistical analysis, Stu-
dent t tests were used to test for differences between WT and rTg4510
mice with each set of axonal transport measurements (1.5, 3, 5, and
10 month olds).
2.5. Tissue processing
Mice were sacriﬁced at 1.5, 3 and 6 months of age (n= 3 per ge-
notype and age). The cortex was dissected and snap frozen and keptat −80 °C until use. For protein extraction, tissues were homoge-
nized in lysis buffer consisting of 50 mM Tris (pH 7.5), 150 mM
NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.0), 1 mM
phenylmethylsulfonyl ﬂuoride, 1% Triton X-100, protease inhibitor
cocktail (Sigma, St Louis, MO, USA) and phosphatase inhibitor cocktail
(Roche Applied Science, Indianapolis, IN, USA). Total protein concentra-
tion was measured using the Bradford Reagent (Thermo Scientiﬁc/
Pierce Biotechnology, Rockford, IL, USA).
Ten micrograms of total protein lysate per sample was resolved by
sodium dodecyl sulfate polyacrylamide gel electrophoresis and trans-
ferred onto a nitrocellulose membrane, and probed with antibodies
against GFAP (1/4000; DAKO, Carpinteria, CA, USA), neuroﬁlament me-
dium (NF-M, 1/4000; Encore, Gainesville, FA, USA), GAPDH (1/5000;
Sigma), hTAU (1/1000; DAKO), PHF-1 (1:1000, gift from Peter Davis),
AT8 (1:1000, Pierce), and pSer262 tau (1:2000, Millipore). Western
blot analysis was performed with infrared dye conjugated secondary
antibodies, IR700 and IR800 (LI-COR Biosciences, Lincoln, NE, USA).
Blots were imaged and processed on an Odyssey® Infrared Imaging
System.
2.6. Immunohistochemistry
Tissue preparation and immunohistochemistry was performed as
described previously (Venkitaramani et al., 2009) with slight modiﬁca-
tions. Brieﬂy, rTg4510 and NTg littermate mice (6-month old) were
anesthetized with 5% isoﬂurane and transcardially perfused with ice-
cold 1× phosphate buffered saline (PBS), followed by 4% paraformalde-
hyde (PFA) in 1× PBS. The head was removed and skinned. The brains
with intact skull were post-ﬁxed overnight in 4% PFA, extensively rinsed
with 1×PBS and decalciﬁed in 5% EDTA in 1× PBS for 2 weeks. The sam-
ples were rinsed with 1× PBS, cryopreserved in 30% sucrose in PBS and
embedded in optimal cutting temperature (O.C.T.). The cryopreserved
samples were sectioned along the sagittal plane at 20 μm thickness
and directly mounted onto pre-cleaned/coated slides. The sections
were stained as described (Venkitaramani et al., 2009) with tau anti-
body (HT7, 1:500, ThermoScientiﬁc/Pierce Biotechnology, Rockford,
IL) and olfactory marker protein (OMP, 1:1000, Wako Chemicals, Rich-
mond, VA). The slides were cover-slipped using ProLong Gold antifade
with DAPI (Invitrogen/Molecular Probes, Eugene, OR). Immunoﬂuores-
cence was visualized using Panoramic 250 scanner (3DHistech) and
Nikon A1R multi-photon confocal microscope.
3. Results
In this study, we measured axonal transport rates in rTg4510
mice and age-matched littermate controls P301L-only (tau+/tta−),
tTA-only (tau−/tta+), and wildtype (WT, NTg) using manganese en-
hanced MRI (MEMRI). Our goal was to investigate the earliest age
point of microtubule-dependent transport dysfunction. We began by
conducting MEMRI in 10-month old rTg4510 mice in order to verify
that it was possible to use this technique without affecting mice viabil-
ity. Upon observation of a reduction in Mn2+ transport in transgenic
mice vs. non-transgenic mice (Fig. 1), we conducted MEMRI experi-
ments at earlier age points.We conducted a nasal lavage ofMnCl2 as de-
scribed in previous MEMRI work (Silva et al., 2004) and thenmeasured
the change in signal intensity over time in the olfactory neuronal layer
(ONL) of the olfactory bulb using MRI. This change in signal intensity
was then used to calculate a slope that is indicative of Mn2+ axonal
transport rate.
In previous studies using rTg4510 mice, the onset of behavioral def-
icits and tau pathology was identiﬁed to be at 4.5 months of age (Yue
et al., 2011, p. 45); (SantaCruz et al., 2005). In addition, volumetric
MRI studies of both the hippocampus and cortical thickness in
rTg4510 mice have indicated the onset of neurodegeneration at around
5 months (Ludvigson et al., 2011). Thus, we began measuring axonal
transport rates at 5 and 10 months of age in rTg4510 mice and their
Fig. 1.Representative images fromolfactory bulb slices fromMEMRI scans ofWTﬁrst cycle
(A) and last cycle (B) and rTg4510 mice ﬁrst cycle (C) and last cycle (D) 10 month old
mice. The left side of the olfactory bulb contains an artifact that is present throughout all
scans. Arrows on the right hand side indicate changes in signal intensity throughout mul-
tiple cycles of MEMRI scans.
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of WT levels at 10 months of age (p-value b 0.005). At 5 months of age,
we measured axonal transport rates of rTg4510 mice at 40% that of WT
levels (p-value b 0.005). Thus, we observe a signiﬁcant reduction in ax-
onal transport rates in rTg4510mice (when compared toWT/NTgmice)
at both 5 and 10 months of age (Fig. 2). These results are consistentwith
studies examining axonal instability, the presence of tau aggregates,
neurodegeneration and behavioral symptoms that have previously
been characterized in this model at 5 months of age.
However, as reported previously, axonal transport deﬁcits have pre-
ceded both the onset of behavioral deﬁcits and amyloid pathology in
other Alzheimer's disease models (Massaad et al., 2010; Smith et al.,
2007). Due to this, and the large body of evidence linking the role of
tau with microtubule stability in neurons (Bertrand et al., 2011;
Chevalier-Larsen and Holzbaur, 2006; Smith et al., 2010; Zhang et al.,
2004), we hypothesized that there could be a reduction in transport
rates at an earlier time point. We observe axonal transport rates at
48% in rTg4510 mice at 3 months of age than that of WT mouse rates
(p-value b 0.005) (Fig. 2). This reduction in axonal transport is a very
early indicator of axonal dysfunction suggesting a signiﬁcant decline
in microtubule-dependent axonal transport. In order to relate theseFig. 2.Axonal transport rates in non-transgenic (WT) and rTg4510 (tau+/tta+) are displayed a
5 (rTg4510) (B), and 10 months with n = 5 (WT) and n = 8 (rTg4510) (C) of age. *p b 0.05, *measurements to an age-dependent axonal transport dysfunction phe-
notype, we also evaluated the progressive change in rates in all three
age groups of rTg4510 mice. Upon normalizing each measurement to
the WT (NTg) control as an indicator of 100% of transport function at
that age, there is approximately a 50% reduction in transport rates at 3
and 5 months, and this rate signiﬁcantly reduces to 30% of the corre-
sponding WT (NTg) mice at 10 months of age (Fig. 2).
In rTg4510mice, the age-dependent loss of neurons and progressive
cognitive dysfunction closely mimic the clinical features of tauopathy
(Ishihara et al., 1999). In our model, tau with the mis-sense mutation
P301L, found in some FTDP-17 cases, is over-expressed in the forebrain
driven by the CaMKII promoter. From previous published data, by
2.5 months, phosphorylated tau protein and neuronal loss can be de-
tected in the forebrain of these mice (SantaCruz et al., 2005). Cognitive
impairment in spatial reference memory and synaptic dysfunction in
hippocampal CA1 pyramidal neurons begin to manifest at 4.5 months
of age (Hoover et al., 2010). In fact, neurodegeneration starts to become
apparent after 5 months of age, primarily in the hippocampal CA1 area,
becomingmore prominent by 9 months of agewhenNFT formation and
gliosis are also present in tauopathy models.
We ﬁrst wanted to determine the exact time point when mutant
hyperphosphorylated tau species start to appear in the cortical region
of rTg4510mice. Corticeswere collected fromboth control andmatched
tau transgene overexpressing mice and probed for the common phos-
phorylated and pathological tau species. As is apparent from our data
there is signiﬁcant neurodegeneration by 6 months of age as seen
from reduced neuroﬁlament levels and increased gliosis (GFAP). How-
ever, we start observing an increased accumulation in phosphorylated
tau species AT8 and pSer262 by 3 months of age (Fig. 3). The mis-
folded pathological tau PHF-1 was detected at 6 months of age but not
in earlier age points.
Next, we wanted to verify that the mutated tau transgene was
expressed in the ONL where we measured axonal transport in the
rTg4510 mice. We collected olfactory bulb tissue from both transgenic
and non-transgenic mice at 6 months of age. Using antibodies against
total human tau (HT-7) and olfactory maker protein (OMP), we per-
formed immunohistochemistry on these samples.
Considering that axonal transport was measured in axonal projec-
tions from olfactory sensory neurons (OSNs) to olfactory bulb (OB),
we determined whether human mutant tau protein was expressed in
this pathway. To establish human tau expression in OSNs as well as
their processes, we performed double-labeling with human tau (Ht7)
and olfactorymarker protein (OMP) antibodies.We detected signiﬁcant
tau (green) immunostaining in the rTg4510 mice as compared to NTg
controls (Fig. 4A). The axonal projections from the OSNs were co-
labeled with tau and OMP (white arrowheads) in rTg4510 mice, but
not in NTg controls (Fig. 4A). Within the olfactory epithelium (OE) of
rTg4510 mice, we observed tau expression in OSNs that co-localized
with OMP (Fig. 4B). This was absent in samples from NTg mice
(Fig. 4B). These results suggest that the axonal transport deﬁcits found
in rTg4510 mice occur prior to the onset of neuroﬁbrillary tau tangle
deposition.t 3 monthswith n=6 (WT) and n=6 (rTg4510) (A), 5 monthswith n=5 (WT) and n=
*p b 0.005.
Fig. 3.Western blots show the expression of various tau species (tau 5, AT8, PHF-1, pTauSer262), neuroﬁlament, GFAP, and GAPDH in the cortex of control and rTg4510mice at 1, 3, and
6 months of age. N = 3 per group.
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It is important to identify an early biomarker of cognitive decline
prior to the onset of tau tangle pathology in neurodegenerative diseases
because cognitive symptoms appear several years prior to the deposits
of tangles in patients (Ingramand Spillantini, 2002). In FTDP-17, familial
mutations have been highly associated with onset of disease (Ingram
and Spillantini, 2002; Wszolek et al., 2006). These mutations in the
MAPT gene cause symptom heterogeneity of age of onset andFig. 4. Representative images of human tau (HT7) and olfactorymarker protein (OMP) staining
double-labeled with antibodies that recognize human tau (HT7, green) and OMP (red). Tau ex
olfactory bulb (OB) in rTg4510 mice and colocalized with OMP (white arrowheads). (B) Expre
mice, tau was expressed in the cell bodies of OSNs located with the olfactory epithelium (OE).Parkinsonian symptoms in FTDP-17 (Combs and Gamblin, 2012). How-
ever, tau tangle pathology is present in several forms of FTDP-17 and
has been identiﬁed as both neuroﬁlaments and oligomers of tau in
human autopsy samples (Combs and Gamblin, 2012; Ingram and
Spillantini, 2002). A large body of literature investigating tau pathology
in vitro and in vivo has implicated that an earlier indicator of cognitive
decline may be a destabilization of microtubules leading to a decrease
in axonal transport (Bearer, 2012; Bertrand et al., 2011; Kim et al.,
2011; Massaad et al., 2010; Serrano et al., 2008; Smith et al., 2010,in 6-month old rTg4510mice. (A) Sagittal brain sections fromNTg and rTg4510micewere
pression was detected in axonal projections from olfactory sensory neurons (OSNs) to the
ssion of human tau and OMP in the olfactory epithelium of NTg and rTg4510. In rTg4510
716 T. Majid et al. / NeuroImage: Clinical 4 (2014) 711–7172007). These studies not only indicate that hyperphosphorylated tau
can be responsible for changes in axonal transport, but also how a de-
cline and deregulation of ATP producing mitochondria at the synapse
of neurons can cause damage to the brain (Bertrand et al., 2011).
Our study investigates this process of axonal transport using a non-
invasive, in vivomethodology (MEMRI) in a mouse model of FTDP-17.
Axonal transport has been measured ex vivo in several cell culture
models as well as in ﬁxed tissue samples from both rat and mouse
models of neurodegenerative diseases (Zwingmann et al., 2004)
(Reddy et al., n.d.). In addition, studies have been conducted using trans-
mission electron microscopy to measure rates of mitochondrial trans-
port in mouse hippocampal neurons (Calkins and Reddy, 2011).
However, very few studies have been able to quantify the rate of axonal
transport in vivo in a disease environment. We and others have previ-
ously demonstrated that MEMRI can speciﬁcally measure microtubule-
based transport, and it has been used in severalmousemodels of disease
(Bertrand et al., 2013; Inoue et al., 2011; Seamster et al., 2012; Serrano
et al., 2008; Smith et al., 2010, 2007; Zhang et al., 2004); (Bertrand
et al., 2013; Kim et al., 2009). Additionally, MEMRI is conducted at phys-
iologically stable temperatures and has been demonstrated to be indic-
ative of axonal transport (Cross et al., 2008; Kim et al., 2011; Massaad
et al., 2010; Millecamps and Julien, 2013; Smith et al., 2010, 2007).
This study conﬁrms and complements these previous studies and uses
MEMRI to measure axonal transport for the ﬁrst time in rTg4510 mice.
In addition, axonal transport has been demonstrated to have an age-
related decrease (Cross et al., 2008), which is then further exacerbated
models with mutations found in neurodegenerative diseases. We ﬁnd,
similar to the models of amyloid pathology, axonal transport deﬁcits
that are present long before the onset of behavioral symptoms as well
as the deposition of aggregates in the brain.
In addition, there are many forms and modiﬁcations of the tau pro-
tein that are present at various stages of disease progression in the
rTg4510 mouse model of FTD. Several studies indicate that the
hyperphosphorylation of tau protein is a key early indicator of dysfunc-
tion within the forebrain prior to the onset of symptoms and neurode-
generation (Hoover et al., 2010; Ishihara et al., 1999); (Hochgräfe
et al., 2013). We conﬁrm these ﬁndings by demonstrating the presence
of hyperphosphorylated tau at Ser262 beginning at 3 months of age,
around the same time that we begin to observe axonal transport deﬁ-
cits. However, the presence of PHF tau is not observed until 6 months
of age in this model, which is a late stage of the disease. This indicates
that the presence of some hyperphosphorylated tau species is enough
to trigger the destabilization and disruption of transport in axons in
FTDP-17. This can then lead to further axonal deﬁcits as the amount in-
creases and pathological tau species accumulate to form aggregates
consisting of neuroﬁbrillary tangles (Berger et al., 2007); (Avila et al.,
2004).
In our study, we also observe the presence of humanmutated tau in
the olfactory bulb of rTg4510mice. Speciﬁcally, tau in the olfactory bulb
is present both in the dendritic processes and the axons of the olfactory
receptor neurons. Deﬁcits in the olfactory system are one of the earliest
symptoms of some neurodegenerative diseases and recent studies have
indicated that copy number variations in olfactory receptor genes are
present in cohorts of patients with these diseases (Ghani et al., 2012;
Shaw et al., 2011; Swaminathan et al., 2012). In parallel to the increase
in severity of symptoms of patients with FTDP-17, the rTg4510 mouse
model demonstrates a progressive memory impairment, neurodegen-
eration, as well as neuroﬁbrillary tangle pathology (Berger et al., 2007;
Kopeikina et al., 2011; Ludvigson et al., 2011; SantaCruz et al., 2005). Re-
cent studies usingmicrotubule stabilizing drugs have shown promising
rescue of pathology in alternate tauopathy models around 5 months of
age (Barten et al., 2012); (Zhang et al., 2005). However, we demonstrate
that tau is altered at 3 months in the rTg4510 mouse model, in concert
with the presence of both hyperphosphorylated tau species and the
presence of tau oligomers at this time point and that rescuemay be pos-
sible even earlier in the progression of tau aggregation and pathology.Bertrand and colleagues have recently demonstrated a correlation
between axonal transport and tau pathology in an alternate model of
FTDP-17 (Bertrand et al., 2013). Their characterization of the JNPL3
model enhances the relevance of our age-related phenotype of axonal
transport deﬁcits within the olfactory bulb. They also report tau tangle
pathology at 9 months of age in their model and correlate that with
tau's presence as tangles within the cell bodies of neurons. Our study
conﬁrms this pathology and adds the presence of alternate phosphory-
lated tau species earlier in the lifespan of our mouse model as a major
biochemical change at the same time point as a functional decline in ax-
onal transport.
In addition, our study supports the extensive literature on the
rTg4510 model in identifying the presence of tau tangle pathology and
astrocyte involvement at 6 months of age. Finally, we are able to dem-
onstrate a visual co-localization of the accumulation of human tau
with the olfactory receptor neurons within the olfactory bulb and the
axonal processes of these neurons in our mouse model. Thus, we are
able to enhance and further the ﬁndings of the JNPL3 study by quantify-
ing multiple biochemical species of tau and correlating early changes
within hyperphosphorylation of human tau isoforms with the onset of
age-dependent axonal transport phenotypes in the rTg4510 mouse
model of FTD. Currently, clinical trials rely upon serum or cerebrospinal
ﬂuid levels of amyloid beta or tau in patients to determine efﬁcacy of
compounds. Additionally, although impairments in axonal transport
have been demonstrated in human cell lines from AD patients (Stokin
and Goldstein, 2006), our study adds evidence of this deﬁcit early in
the pathology of fronto-temporal dementia. Age-related declines in axo-
nal transport (Cross et al., 2008) are exacerbated with a disease-causing
mutation both in the case of amyloid beta as well as tauwithin the olfac-
tory bulb. Clinically, impairments in olfaction have also been demon-
strated as early indicators of the onset of neurodegeneration (Davies
et al., 1993; Shaw et al., 2011). Thus, we submit that further investiga-
tions into early indicators of olfactory receptor changes and axonal trans-
port rates in patients may provide insight into neurodegenerative
disease pathology in the future.
In conclusion, we demonstrate a very early phenotype of axonal
transport deﬁcits in the rTg4510 mouse model of FTDP-17 prior to the
onset of tau tangle pathology. Our study complements the growing
body of evidence supporting the use of MEMRI as a reliable measure-
ment of in vivo axonal transport rates and as a diagnostic indicator of
cognitive decline prior to the presence of overt behavioral symptoms.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2014.02.005.Acknowledgments
The authors would like to thank Chris P. Jew, Ximin Zhou, and
Taneasha W. Washington for their assistance and care of the mice
during the course of this study. Funding for this work was provided
by: Molecular Biology on Aging Training Grant NIH/NIA
T32AG000183-20, NIH/NIA (AG029977, RGP), NIH/NINDS (NS048884,
HCL), and the Belfer Neurodegeneration Consortium (MKJ, DVV, HCL,
RGP).References
Akins, M.R., Greer, C.A., 2006. Cytoskeletal organization of the developingmouse olfactory
nerve layer. J. Comp. Neurol. 494, 358–367.
Avila, J., Lucas, J.J., Pérez, M., Hernández, F., 2004. Role of tau protein in both physiological
and pathological conditions. Physiol. Rev. 84, 361–384.
Barten, D.M., Fanara, P., Andorfer, C., Hoque, N., Wong, P.Y.A., Husted, K.H., Cadelina, G.W.,
DeCarr, L.B., Yang, L., Liu, V., Fessler, C., Protassio, J., Riff, T., Turner, H., Janus, C.G.,
Sankaranarayanan, S., Polson, C., Meredith, J.E., Gray, G., Hanna, A., Olson, R.E., Kim,
S.-H., Vite, G.D., Lee, F.Y., Albright, C.F., 2012. Hyperdynamic microtubules, cognitive
deﬁcits, and pathology are improved in tau transgenic mice with low doses of the
microtubule-stabilizing agent BMS-241027. J. Neurosci. 32, 7137–7145.
Bearer, E.L., 2012. HSV, axonal transport and Alzheimer's disease: in vitro and in vivo ev-
idence for causal relationships. Futur. Virol. 7, 885–899.
717T. Majid et al. / NeuroImage: Clinical 4 (2014) 711–717Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., Wszolek, Z., Ashe, K.,
Knight, J., Dickson, D., Andorfer, C., Rosenberry, T.L., Lewis, J., Hutton, M., Janus, C.,
2007. Accumulation of pathological tau species and memory loss in a conditional
model of tauopathy. J. Neurosci. 27, 3650–3662.
Bertrand, A.M., Hoang, D., Khan, U.Z., Wadghiri, Y., 2011. From axonal transport to mito-
chondrial trafﬁcking: what can we learn from manganese-enhanced MRI studies in
mouse models of Alzheimer's disease? Curr. Med. Imaging Rev. 7, 16–27.
Bertrand, A., Khan, U., Hoang, D.M., Novikov, D.S., Krishnamurthy, P., RajamohamedSait,
H.B., Little, B.W., Sigurdsson, E.M., Wadghiri, Y.Z., 2013. Non-invasive, in vivo moni-
toring of neuronal transport impairment in a mouse model of tauopathy using
MEMRI. NeuroImage 64, 693–702.
Bird, T.D., Nochlin, D., Poorkaj, P., Cherrier, M., Kaye, J., Payami, H., Peskind, E., Lampe, T.H.,
Nemens, E., Boyer, P.J., Schellenberg, G.D., 1999. A clinical pathological comparison of
three families with frontotemporal dementia and identical mutations in the tau gene
(P301L). Brain 122, 741–756.
Calkins, M.J., Reddy, P.H., 2011. Amyloid beta impairs mitochondrial anterograde trans-
port and degenerates synapses in Alzheimer's disease neurons. Biochim. Biophys.
Acta 1812, 507–513.
Chevalier-Larsen, E., Holzbaur, E.L.F., 2006. Axonal transport and neurodegenerative dis-
ease. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1762, 1094–1108.
Combs, B., Gamblin, T.C., 2012. FTDP-17 tau mutations induce distinct effects on aggrega-
tion and microtubule interactions. Biochemistry (Mosc) 51, 8597–8607.
Cross, D.J., Flexman, J.A., Anzai, Y., Maravilla, K.R., Minoshima, S., 2008. Age-related de-
crease in axonal transport measured by MR imaging in vivo. NeuroImage 39,
915–926.
Davies, D.C., Brooks, J.W., Lewis, D.A., 1993. Axonal loss from the olfactory tracts in
Alzheimer's disease. Neurobiol. Aging 14, 353–357.
Fu-Hua Wang, P.A., Appelkvist, Paulina, Klason, Tomas, Gissberg, Olle, Bogstedt, Anna,
Eliason, Kristina, Martinsson, Stefan, Briem, Sveinn, Andersson, Anders, Sandra, A.,
Visser, G., Ivarsson, Magnus, Lindberg, Mattias, Agerman, Karin, Sandin, Johan,
2012. Decreased axonal transport rates in the Tg2576 APP transgenic mouse: im-
provement with the gamma-secretase inhibitor MRK-560 as detected by manga-
nese-enhanced MRI. European Journal of Neuroscience 36 (9), 3165–3172.
Ghani, M., Pinto, D., Lee, J.H., Grinberg, Y., Sato, C., Moreno, D., Scherer, S.W., Mayeux, R.,
George-Hyslop, P.S., Rogaeva, E., 2012. Genome-wide survey of large rare copy num-
ber variants in Alzheimer's disease among Caribbean Hispanics. G3 Genes Genomes
Genet. 2, 71–78.
Goedert, M., Spillantini, M.G., 2011. Pathogenesis of the tauopathies. J. Mol. Neurosci. MN
45, 425–431.
Goedert, M., Ghetti, B., Spillantini, M.G., 2012. Frontotemporal dementia: implications for
understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006254.
Hochgräfe, K., Sydow, A., Mandelkow, E.-M., 2013. Regulatable transgenic mouse models
of Alzheimer disease: onset, reversibility and spreading of Tau pathology. FEBS J 280
(18), 4371–4381.
Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., Carlson,
G.A., Lanier, L.M., Yuan, L.-L., Ashe, K.H., Liao, D., 2010. Taumislocalization to dendritic
spines mediates synaptic dysfunction independently of neurodegeneration. Neuron
68, 1067–1081.
Ingram, E.M., Spillantini, M.G., 2002. Tau gene mutations: dissecting the pathogenesis of
FTDP-17. Trends Mol. Med. 8, 555–562.
Inoue, T., Majid, T., Pautler, R.G., 2011. Manganese enhanced MRI (MEMRI): neurophysi-
ological applications. Rev. Neurosci. 22, 675–694.
Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M.K., Trojanowski, J.Q., Lee, V.M., 1999.
Age-dependent emergence and progression of a tauopathy in transgenic mice over-
expressing the shortest human tau isoform. Neuron 24, 751–762.
Karch, C.M., Jeng, A.T., Goate, A.M., 2012. Extracellular Tau levels are inﬂuenced by vari-
ability in Tau that is associated with tauopathies. J. Biol. Chem. 287, 42751–42762.
Kim, J., Choi, I.-Y., Michaelis, M.L., Lee, P., 2011. Quantitative in vivo measurement of early
axonal transport deﬁcits in a triple transgenic mouse model of Alzheimer's disease
using manganese-enhanced MRI. NeuroImage 56, 1286–1292.
Kim,Choi, I., Michaelis, M., Lee, S., 2009. Early Impaired Axonal Transport in a Triple Trans-
genic Mouse Model of Alzheimer's Disease. , 17 (540).
Kopeikina, K.J., Carlson, G.A., Pitstick, R., Ludvigson, A.E., Peters, A., Luebke, J.I., Kofﬁe, R.M.,
Frosch, M.P., Hyman, B.T., Spires-Jones, T.L., 2011. Tau accumulation causesmitochon-
drial distribution deﬁcits in neurons in a mouse model of tauopathy and in human
Alzheimer's disease brain. Am. J. Pathol. 179, 2071–2082.
Lasagna-Reeves, C.A., Castillo-Carranza, D.L., Sengupta, U., Guerrero-Munoz, M.J., Kiritoshi,
T., Neugebauer, V., Jackson, G.R., Kayed, R., 2012. Alzheimer brain-derived tau oligo-
mers propagate pathology from endogenous tau. Sci. Rep. 2.
Liu, N., 2000. Regional distribution of protein kinases in normal and odor-deprivedmouse
olfactory bulbs. Chem. Senses 25, 401–406.
Ludvigson, A.E., Luebke, J.I., Lewis, J., Peters, A., 2011. Structural abnormalities in the cor-
tex of the rTg4510mouse model of tauopathy: a light and electron microscopy study.
Brain Struct. Funct. 216, 31–42.
Massaad, C.A., Amin, S.K., Hu, L., Mei, Y., Klann, E., Pautler, R.G., 2010.Mitochondrial super-
oxide contributes to blood ﬂow and axonal transport deﬁcits in the Tg2576 mouse
model of Alzheimer's disease. PLoS ONE 5, e10561.
Millecamps, S., Julien, J.-P., 2013. Axonal transport deﬁcits and neurodegenerative dis-
eases. Nat. Rev. Neurosci. 14, 161–176.Perez, P.D., Hall, G., Kimura, T., Ren, Y., Bailey, R.M., Lewis, J., Febo, M., Sahara, N., 2013. In
vivo functional brain mapping in a conditional mouse model of human tauopathy
(tau(P301L)) reveals reduced neural activity in memory formation structures. Mol.
Neurodegener. 8, 9.
Reddy, P.H., Tripathi, R., Troung, Q., Tirumala, Reddy, T.P., Anekonda, V., Shirendeb, U.P.,
Calkins, M.J., Reddy, A.P., Mao, P., Manczak, M., n.d. Abnormal mitochondrial dynam-
ics and synaptic degeneration as early events in Alzheimer's disease: implications to
mitochondria-targeted antioxidant therapeutics. Biochim. Biophys. Acta BBA - Mol.
Basis Dis.
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A.,
DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash,
A., Kuskowski, M., Hyman, B., Hutton, M., Ashe, K.H., 2005. Tau suppression in a neuro-
degenerative mouse model improves memory function. Science 309, 476–481.
Sbarbati, A., Calderan, L., Nicolato, E., Marzola, P., Lunati, E., Donatella, B., Bernardi, P.,
Osculati, F., 2002. Magnetic resonance imaging of the rat Harderian gland. J. Anat.
201, 231–238.
Schulz, K.L., Eckert, A., Rhein, V., Mai, S., Haase, W., Reichert, A.S., Jendrach, M., Müller, W.
E., Leuner, K., 2012. A new link to mitochondrial impairment in tauopathies. Mol.
Neurobiol. 46, 205–216.
Seamster, P.E., Loewenberg, M., Pascal, J., Chauviere, A., Gonzales, A., Cristini, V., Bearer, E.
L., 2012. Quantitative measurements and modeling of cargo-motor interactions dur-
ing fast transport in the living axon. Phys. Biol. 9, 055005.
Serrano, F., Deshazer, M., Smith, K.D.B., Ananta, J.S., Wilson, L.J., Pautler, R.G., 2008.
Assessing transneuronal dysfunction utilizing manganese-enhanced MRI (MEMRI).
Magn. Reson. Med. 60, 169–175.
Shaw, C.A., Li, Y., Wiszniewska, J., Chasse, S., Zaidi, S.N.Y., Jin, W., Dawson, B., Wilhelmsen,
K., Lupski, J.R., Belmont, J.W., Doody, R.S., Szigeti, K., 2011. Olfactory copy number as-
sociation with age at onset of Alzheimer disease. Neurology 76, 1302–1309.
Silva, A.C., Lee, J.H., Aoki, I., Koretsky, A.P., 2004. Manganese‐enhanced magnetic reso-
nance imaging (MEMRI): methodological and practical considerations. NMR Biomed.
17, 532–543.
Smith, K.D.B., Kallhoff, V., Zheng, H., Pautler, R.G., 2007. In vivo axonal transport rates de-
crease in a mouse model of Alzheimer's disease. NeuroImage 35, 1401–1408.
Smith, K.D.B., Peethumnongsin, E., Lin, H., Zheng, H., Pautler, R.G., 2010. Increased human
wildtype tau attenuates axonal transport deﬁcits caused by loss of APP in mouse
models. Magn. Reson. Insights 4, 11–18.
Snowden, J.S., Neary, D., Mann, D.M.A., 2002. Frontotemporal dementia. Br. J. Psychiatry
180, 140–143.
Stokin, G.B., Goldstein, L.S.B., 2006. Axonal transport and Alzheimer's disease. Annu. Rev.
Biochem. 75, 607–627.
Swaminathan, S., Huentelman, M.J., Corneveaux, J.J., Myers, A.J., Faber, K.M., Foroud, T.,
Mayeux, R., Shen, L., Kim, S., Turk, M., Hardy, J., Reiman, E.M., Saykin, A.J., the
Alzheimer's Disease Neuroimaging Initiative (ADNI) and the NIA-LOAD/NCRAD Fam-
ily Study Group, 2012. Analysis of copy number variation in Alzheimer's disease in a
cohort of clinically characterized and neuropathologically veriﬁed individuals. PLoS
ONE 7, e50640.
Trimmer, P.A., Borland, M.K., 2005. Differentiated Alzheimer's disease transmitochondrial
cybrid cell lines exhibit reduced organelle movement. Antioxid. Redox Signal. 7,
1101–1109.
Venkitaramani, D.V., Paul, S., Zhang, Y., Kurup, P., Ding, L., Tressler, L., Allen, M., Sacca, R.,
Picciotto, M.R., Lombroso, P.J., 2009. Knockout of striatal enriched protein tyrosine
phosphatase in mice results in increased ERK1/2 phosphorylation. Synap. N Y C 63,
69–81.
Wszolek, Z.K., Tsuboi, Y., Ghetti, B., Pickering-Brown, S., Baba, Y., Cheshire, W.P., 2006.
Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
Orphanet J. Rare Dis. 1, 30.
Yuan, A., Kumar, A., Peterhoff, C., Duff, K., Nixon, R.A., 2008. Axonal transport rates in vivo
are unaffected by tau deletion or overexpression in mice. J. Neurosci. Off. J. Soc.
Neurosci. 28, 1682.
Yue, M., Hanna, A., Wilson, J., Roder, H., Janus, C., 2011. Sex difference in pathology and
memory decline in rTg4510 mouse model of tauopathy. Neurobiol. Aging 32,
590–603.
Zhang, B., Higuchi, M., Yoshiyama, Y., Ishihara, T., Forman, M.S., Martinez, D., Joyce, S.,
Trojanowski, J.Q., Lee, V.M.-Y., 2004. Retarded axonal transport of R406W mutant
tau in transgenic mice with a neurodegenerative tauopathy. J. Neurosci. Off. J. Soc.
Neurosci. 24, 4657–4667.
Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E.B., Xie, S.X.,
Joyce, S., Li, C., Toleikis, P.M., Lee, V.M.-Y., Trojanowski, J.Q., 2005. Microtubule-
binding drugs offset tau sequestration by stabilizing microtubules and reversing
fast axonal transport deﬁcits in a tauopathy model. Proc. Natl. Acad. Sci. U. S. A.
102, 227–231.
Zhang, Y., Zhang, H.-M., Shi, Y., Lustgarten, M., Li, Y., Qi, W., Zhang, B.-X., Van Remmen,
H., 2010. Loss of manganese superoxide dismutase leads to abnormal growth and
signal transduction in mouse embryonic ﬁbroblasts. Free Radic. Biol. Med. 49,
1255–1262.
Zwingmann, C., Leibfritz, D., Hazell, A.S., 2004. Brain energymetabolism in a sub-acute rat
model of manganese neurotoxicity: an ex vivo nuclear magnetic resonance study
using [1-13C]glucose. Neurotoxicology 25, 573–587.
